The Moderna $1.3B contingent payment decision from the Federal Circuit is pending and represents the next major catalyst. Monitor the 10-Q filing for full details on the tender offer impact and ongoing litigation costs.
Drugs in focus
ABUS drug pipeline →AB-101
● Neutral Named in this press release- Impact
- Phase
- Phase 1a/1b
- Time to market
- AB-101 is in Phase 1a/1b trials; even if development proceeds smoothly, a potential approval is likely several years away given the early stage and the need for larger Phase 2 and Phase 3 trials.
- Next catalyst
- None dated
What to watchThe next catalyst for ABUS is Q3 2026 earnings on November 11, 2026 (tomorrow), which may include updates on AB-101's clinical development plans now that the FDA hold is lifted. For AB-101 specifically, watch for the company to announce the next phase of clinical trials in chronic hepatitis B patients. The clinical hold lift removes a key overhang, but the drug remains early-stage with no pivotal readout or PDUFA date on the horizon.
Price Chart
Executive Summary
Arbutus reported Q3 2026 net income of $59.1M ($0.30 per share) vs a net loss of $7.7M in Q3 2025, driven by a $67.3M dividend from Genevant. Revenue was $0.3M, below the $1.4M consensus. The company completed a $230M tender offer returning capital to shareholders and announced expanded LNP patent litigation against Pfizer/BioNTech.
Key Financial Metrics
Key Facts
- Q3 2026 net income of $59.1M vs net loss of $7.7M in Q3 2025
- Total revenue of $0.3M, down from $0.5M in Q3 2025 and below $1.4M consensus
- Cash, cash equivalents and marketable securities of $337.5M as of Sept 30, 2026
- Completed $230M tender offer in Oct 2026, repurchasing 46M shares (23% of outstanding) at $5.00/share
- Received $67.3M cash dividend from Genevant in Sept 2026
- Filed new LNP patent infringement lawsuits in Japan and amended Canadian case against Pfizer/BioNTech
- FDA lifted clinical hold on AB-101 (oral PD-L1 inhibitor) IND in Oct 2026
- Moderna settlement: $178.4M received in July 2026; $1.3B contingent payment awaits Federal Circuit ruling
- R&D expenses fell to $2.6M from $5.8M due to workforce reduction and discontinued in-house research
- G&A expenses rose to $8.0M from $3.0M due to one-time executive bonuses related to Moderna settlement
Financial Impact
Net income of $59.1M vs consensus EPS of -$0.03; revenue of $0.3M vs $1.4M consensus; cash position $337.5M
Risk Factors
- Revenue decline and reliance on non-recurring litigation income and dividends
- Uncertainty around Moderna $1.3B contingent payment pending Federal Circuit ruling
- Patent litigation against Pfizer/BioNTech is early-stage with no near-term resolution
- Clinical-stage pipeline (imdusiran, AB-101) has no approved products and faces development risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3399371 |
Track record
25 reports on ABUS
3 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +11.55% at T+20 after the Aug 12, 2026 report. 6 of 12 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $4.04 Now $4.04 −0.00% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $4.04 Now $4.04 −0.00% settles Feb 16
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $4.07 Now $4.04 −0.74% settles Feb 12
- Nov 12, 20264d ago 8-K Neutral 2/10 Entry $4.03 Now $4.04 +0.25% settles Feb 10
- Nov 10, 20266d ago 8-K Neutral 5/10 Entry $3.82 Now $4.04 +5.76% settles Feb 8
- Nov 10, 20266d ago Press Release Neutral 4/10 Viewing No price data
- Nov 6, 202610d ago Institutional Cluster Bearish 4/10 Entry $3.66 Now $4.04 −10.53% settles Feb 4
- Oct 22, 202625d ago 8-K Bullish 6/10 Entry $4.21 Now $4.04 −4.04% settles Jan 20
- Oct 22, 202625d ago Press Release Bullish 7/10 Entry $4.21 Now $4.04 −4.04% settles Jan 20
- Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $4.18 Now $4.04 −3.35% settles Jan 5
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers